Adell Harriman & Carpenter Inc. Sells 24,646 Shares of Boston Scientific Corporation $BSX

Posted by George Bondi on Jul 15th, 2026

Boston Scientific logo Adell Harriman & Carpenter Inc. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 44.7% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 30,509 shares of the medical equipment provider’s stock after selling 24,646 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Boston Scientific were worth $1,914,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Checchi Capital Advisers LLC lifted its holdings in shares of Boston Scientific by 10.2% during the first quarter. Checchi Capital Advisers LLC now owns 11,158 shares of the medical equipment provider’s stock worth $700,000 after buying an additional 1,032 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Boston Scientific by 17.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 10,150 shares of the medical equipment provider’s stock valued at $637,000 after purchasing an additional 1,500 shares during the period. Avantax Planning Partners Inc. grew its position in shares of Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after purchasing an additional 201 shares in the last quarter. HBW Advisory Services LLC increased its holdings in shares of Boston Scientific by 24.2% during the first quarter. HBW Advisory Services LLC now owns 4,941 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 962 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of Boston Scientific by 0.9% in the first quarter. Principal Financial Group Inc. now owns 1,686,453 shares of the medical equipment provider’s stock valued at $105,825,000 after buying an additional 14,795 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $42.71 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $42.25 and a 52 week high of $109.50. The stock has a market capitalization of $63.48 billion, a P/E ratio of 17.87, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The stock has a fifty day moving average of $48.88 and a 200-day moving average of $66.76.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Mizuho cut their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. UBS Group dropped their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Finally, Barclays reduced their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.72.

Check Out Our Latest Stock Report on BSX

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

Negative Sentiment: Boston Scientific’s stock fell in the latest session even as the broader market gained, signaling investors are rotating away from the name or reacting to company-specific concerns. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Negative Sentiment: The company initiated several voluntary Class II recalls of CRE and CRE Pro Wireguided endoscopy devices worldwide after potential sterile breaches in packaging, affecting tens of thousands of units and raising quality-control and regulatory risk concerns. Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?
Neutral Sentiment: Royal Bank of Canada lowered its price target on BSX to $85 from $100, but kept an “outperform” rating, suggesting the long-term view remains constructive despite recent pressure. Boston Scientific price target lowered by Royal Bank Of Canada
Neutral Sentiment: Boston Scientific was also mentioned in a market piece highlighting large-cap and sub-$50 stocks, but the item did not include any new company-specific catalyst. 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.